Abstract 1062P
Background
Some studies, including a recent meta-analysis, observed that the circadian rhythm of immune cell’s proliferation and destruction may influence progression-free and overall survival in metastatic cancer treated with immunotherapy (IO). This study aims to assess whether such differences persist in patients with locally advanced non-small-cell lung cancer (NSCLC) undergoing radical concurrent chemo/radiotherapy (CRT) and IO consolidation depending on the time of day of IO administration.
Methods
For this study, all the histologically confirmed patients with irresectable NSCLC PDL1 >1% treated with radical concurrent CRT and IO consolidation (PACIFIC protocol) from 2018 to 2023 in our hospital were included. These patients were categorized depending on the median time of IO administration in two groups: morning (before 3pm) or afternoon group (after 3 pm).
Results
A total of 41 patients were identified. The mean age was 65.4 years (range 45-78) of which 34 were males (82.9%) and 24 presented squamous cell carcinoma histology (58.5%). The morning group included 28 patients (68%), receiving 50% or more doses of IO before 3 pm, while the afternoon group included 13 patients (32%), receiving less than 50% of doses before 3pm. Patients received a mean of 7.78 months (range 1-13) of consolidation IO after radical concurrent CRT. Progression-free survival (PFS) was significantly better in the morning group compared to the afternoon group. Median PFS is not achieved vs 13 months (p=0.017; Hazard Ratio 3.04, 95% CI 1.17-7.91, p=0.023). The 1-year PFS rates were 68.5% vs. 51.9% and mean PFS was 33 vs. 16.4 months. Overall survival (OS) favoured the morning group but did not reach statistical significance. Median OS 44 vs. 31 months (p=0.21; HR 1.97, 95% CI 0.68-5.74). The 1-year OS rates were 91.8% vs. 84.6%, and 3year OS rates were 66.4% vs 32.6%.
Conclusions
This retrospective analysis indicates that patients treated preferentially before 3pm exhibit a better disease control than those treated onwards. Preferential treatment in the morning may enhance disease control and improve OS. This encourages the release of a prospective clinical trial.
Clinical trial identification
CEIM code 2023.217; Approved on 07/11/2023.
Editorial acknowledgement
Legal entity responsible for the study
Institut Català d'Oncologia - Girona and IDIBGI.
Funding
IDIBGI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
937P - Pain, fatigue and depression symptom cluster in head and neck cancer survivors
Presenter: Iakov Bolnykh
Session: Poster session 03
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03